The estimated Net Worth of Geoffrey E. Harris is at least $575 millier dollars as of 14 January 2019. Mr. Harris owns over 100,000 units of Cancer Genetics stock worth over $575,025 and over the last 10 years he sold CGIX stock worth over $0. In addition, he makes $0 as Director at Cancer Genetics.
Geoffrey has made over 6 trades of the Cancer Genetics stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of CGIX stock worth $23,000 on 14 January 2019.
The largest trade he's ever made was buying 100,000 units of Cancer Genetics stock on 14 January 2019 worth over $23,000. On average, Geoffrey trades about 9,196 units every 103 days since 2014. As of 14 January 2019 he still owns at least 127,500 units of Cancer Genetics stock.
You can see the complete history of Mr. Harris stock trades at the bottom of the page.
Geoffrey Eric Harris is the Director of the Company. He served as a managing director and co-head of the healthcare investment banking group at Cantor Fitzgerald, and from 2009-2011, he held a similar position at Gleacher & Company. Mr. Harris is also currently on the board of directors of GoNow Doctors (Nasdaq:ANCI), a healthcare services company, MYnd Analytics (Nasdaq: CNSO), a data analysis company focused on improving mental health care, Amperic, Inc., a privately-held technology company, and PointRight Inc., a privately-held software company. Mr. Harris graduated from MIT's Sloan School of Management with an M.S. in Finance Management.
Geoffrey Harris is 56, he's been the Director of Cancer Genetics since 2016. There are 6 older and 1 younger executives at Cancer Genetics. The oldest executive at Cancer Genetics Inc. is John Pappajohn, 90, who is the Non-Executive Chairman of the Board.
Geoffrey's mailing address filed with the SEC is 201 NJ-17, Rutherford, NJ 07070, USA.
Over the last 12 years, insiders at Cancer Genetics have traded over $1,720,897 worth of Cancer Genetics stock and bought 3,891,559 units worth $4,573,241 . The most active insiders traders include John Pappajohn, Tommy G Thompson et John A Roberts. On average, Cancer Genetics executives and independent directors trade stock every 35 days with the average trade being worth of $340,207. The most recent stock trade was executed by John A Roberts on 31 January 2019, trading 185,436 units of CGIX stock currently worth $42,650.
Cancer Genetics executives and other stock owners filed with the SEC include: